just got an email from michelle miller advising of the award
here is the body of the email
Dr Carolyn Luscombe, Head of Research and Development, has received an award at the HIV DART and Emerging Viruses 2018 in Miami, Florida for the presentation entitled
“BIT225-009: Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial”.
The award is an acknowledgement of the importance of the outcomes from the Phase 2 trial data presented, as well as the robustness of the science underlying the Company’s programs."
Well done MM and Carolyn.
I will buy when I see fit, dyor
BIT Price at posting:
15.0¢ Sentiment: Buy Disclosure: Not Held
